Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prostate cancer

Stratifying intermediate-risk patients for radiotherapy

Radiotherapy is not a well-established option for men with intermediate-risk prostate cancer and further substratification of these patients could help to guide treatment decisions. Researchers have developed a new risk-classification system for intermediate-risk patients undergoing dose-escalated external-beam radiation therapy, but how effective is this system?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Edge, S. B. et al. AJCC Cancer Staging Manual, 7th edition 457–468 (Springer, New York, 2010).

    Google Scholar 

  2. Mohler, J. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw. 8, 162–200 (2010).

    Article  CAS  Google Scholar 

  3. Kuykendal, A. R. et al. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann. Oncol. 24, 1338–1343 (2013).

    Article  CAS  Google Scholar 

  4. D'Ambrosio, D. J. et al. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 67, 1082–1087 (2007).

    Article  Google Scholar 

  5. Vance, S. M. et al. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 83, 940–946 (2012).

    Article  Google Scholar 

  6. Qian, Y. et al. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 81, e135–e142 (2011).

    Article  Google Scholar 

  7. Zumsteg, Z. S. et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2013.03.033.

  8. Castle, K. O. et al. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int. J. Radiat. Oncol. Biol. Phys. 85, 693–699 (2013).

    Article  Google Scholar 

  9. Stoyanova, R. et al. The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms. Cancer 119, 1080–1088 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buyyounouski, M. Stratifying intermediate-risk patients for radiotherapy. Nat Rev Urol 10, 438–439 (2013). https://doi.org/10.1038/nrurol.2013.142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2013.142

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing